About OptiNose
OptiNose is a company based in Morrisville (United States) founded in 2000 was acquired by Paratek Pharma in March 2025. OptiNose has raised $120.5 million across 10 funding rounds from investors including Fidelity Investments, Paratek Pharma and bpcruk. The company has 132 employees as of December 31, 2023. OptiNose offers products and services including XHANCE, ONZETRA, and Xsail. OptiNose operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others.
- Headquarter Morrisville, United States
- Employees 132 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Optinose Us, Inc.
-
Annual Revenue
$76.28 M (USD)2as on Dec 31, 2022
-
Net Profit
-
EBITDA
-
Total Equity Funding
$120.5 M (USD)
in 10 rounds
-
Latest Funding Round
$4.68 M (USD), Post-IPO
May 10, 2024
-
Investors
Fidelity Investments
& 6 more
-
Employee Count
132
as on Dec 31, 2023
-
Acquired by
Paratek Pharma
(Mar 19, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OptiNose
OptiNose offers a comprehensive portfolio of products and services, including XHANCE, ONZETRA, and Xsail.
Delivers steroid for treating nasal inflammation in ENT conditions.
Exhalation delivery system for migraine relief medication.
Nasal device for effective medication administration in allergies.
People of OptiNose
Unlock access to complete
Funding Insights of OptiNose
OptiNose has successfully raised a total of $120.5M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.68 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $4.7M
-
First Round
First Round
(07 Jun 2010)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Post-IPO - OptiNose | Valuation |
investors |
|
| Nov, 2021 | Amount | Post-IPO - OptiNose | Valuation |
investors |
|
| Aug, 2020 | Amount | Post-IPO - OptiNose | Valuation |
investors |
|
Investors in OptiNose
OptiNose has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paratek Pharma and bpcruk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Tech & life science focused stage agnostic VC firm investing primarily in Western Europe
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by OptiNose
Financial Statements - OptiNose
Optinose Comparisons
Competitors of OptiNose
OptiNose operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Intranasal delivery technology for CNS diseases is developed.
|
|
| domain | founded_year | HQ Location |
Developer of products for the treatment of acute and intermittent conditions
|
|
| domain | founded_year | HQ Location |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Inhalation devices for medical applications are developed by Iconovo.
|
Frequently Asked Questions about OptiNose
OptiNose was founded in 2000 and raised its 1st funding round 10 years after it was founded.
OptiNose is headquartered in Morrisville, United States.
OptiNose is a funded company, having raised a total of $120.5M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $250K, raised on Jun 07, 2010.
As of Dec 31, 2023, the latest employee count at OptiNose is 132.
Annual revenue of OptiNose is $76.28M as on Dec 31, 2022.
OptiNose is a developer of smart devices for nasal drug delivery. The drug delivery devices can be used for powder and liquid formulations. Pipeline includes candidates for chronic nasal inflammatory disease, migraine and autism.
OptiNose's top competitors include MannKind Corp, Impel NeuroPharma and Qnovia.
OptiNose offers XHANCE, ONZETRA, and Xsail.
OptiNose has 7 investors. Key investors include Fidelity Investments, Paratek Pharma, bpcruk, Athyrium Capital Management, and Avista Capital Partners.